Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation

Joshua E. Muscat, Gang Chen, Ashley Knipe, Steven D. Stellman, Philip Lazarus, John P. Richie

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Menthol is a controversial cigarette additive because its physiologic or pharmacologic effects may possibly increase the risk for cancer and its targeted market is the Black community. In a community-based cross-sectional study on 525 Black and White volunteers, we compared levels of urinary and plasma cotinine, plasma thiocyanate, urinary 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1- butanol (NNAL), and its detoxified form (NNAL-Gluc) between menthol and nonmenthol smokers. In regression models that adjusted for daily cigarette intake, no significant differences were observed in the concentration of these biomarkers by menthol status in both races. There was no significant association between high Fagerstrom nicotine dependence scores and the use of menthol cigarettes (odds ratio, 1.1; 95% confidence interval, 0.6-2.0), but an increased risk was observed with smoking a cigarette soon (≤30 minutes) after waking (odds ratio, 2.1; 95% confidence interval, 1.0-3.8). The ratio of NNAL-Gluc to NNAL, a possible indicator of lung cancer risk, was significantly lower in menthol versus nonmenthol smokers. The NNAL-Gluc/NNAL ratio was 34% lower in Whites (P < 0.01) and 22% lower in Blacks. In subsequent human liver microsome studies, menthol inhibited the rate of NNAL-O-glucuronidation and NNAL-N-glucuronidation. Collectively, these results show that menthol does not affect biological exposure to tobacco smoke constituents but indicates that menthol might inhibit the detoxification of the potent lung carcinogen NNAL.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Menthol
Tobacco Use Disorder
Smoke
Tobacco
Tobacco Products
Odds Ratio
Confidence Intervals
Cotinine
1-Butanol
Liver Microsomes
Carcinogens
Volunteers
Lung Neoplasms
Cross-Sectional Studies
Biomarkers
Smoking
Lung

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

@article{7e98219efbc04472b05742f10ae3af31,
title = "Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation",
abstract = "Menthol is a controversial cigarette additive because its physiologic or pharmacologic effects may possibly increase the risk for cancer and its targeted market is the Black community. In a community-based cross-sectional study on 525 Black and White volunteers, we compared levels of urinary and plasma cotinine, plasma thiocyanate, urinary 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1- butanol (NNAL), and its detoxified form (NNAL-Gluc) between menthol and nonmenthol smokers. In regression models that adjusted for daily cigarette intake, no significant differences were observed in the concentration of these biomarkers by menthol status in both races. There was no significant association between high Fagerstrom nicotine dependence scores and the use of menthol cigarettes (odds ratio, 1.1; 95{\%} confidence interval, 0.6-2.0), but an increased risk was observed with smoking a cigarette soon (≤30 minutes) after waking (odds ratio, 2.1; 95{\%} confidence interval, 1.0-3.8). The ratio of NNAL-Gluc to NNAL, a possible indicator of lung cancer risk, was significantly lower in menthol versus nonmenthol smokers. The NNAL-Gluc/NNAL ratio was 34{\%} lower in Whites (P < 0.01) and 22{\%} lower in Blacks. In subsequent human liver microsome studies, menthol inhibited the rate of NNAL-O-glucuronidation and NNAL-N-glucuronidation. Collectively, these results show that menthol does not affect biological exposure to tobacco smoke constituents but indicates that menthol might inhibit the detoxification of the potent lung carcinogen NNAL.",
author = "Muscat, {Joshua E.} and Gang Chen and Ashley Knipe and Stellman, {Steven D.} and Philip Lazarus and Richie, {John P.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-08-0744",
language = "English (US)",
volume = "18",
pages = "35--41",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation. / Muscat, Joshua E.; Chen, Gang; Knipe, Ashley; Stellman, Steven D.; Lazarus, Philip; Richie, John P.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 1, 01.01.2009, p. 35-41.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation

AU - Muscat, Joshua E.

AU - Chen, Gang

AU - Knipe, Ashley

AU - Stellman, Steven D.

AU - Lazarus, Philip

AU - Richie, John P.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Menthol is a controversial cigarette additive because its physiologic or pharmacologic effects may possibly increase the risk for cancer and its targeted market is the Black community. In a community-based cross-sectional study on 525 Black and White volunteers, we compared levels of urinary and plasma cotinine, plasma thiocyanate, urinary 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1- butanol (NNAL), and its detoxified form (NNAL-Gluc) between menthol and nonmenthol smokers. In regression models that adjusted for daily cigarette intake, no significant differences were observed in the concentration of these biomarkers by menthol status in both races. There was no significant association between high Fagerstrom nicotine dependence scores and the use of menthol cigarettes (odds ratio, 1.1; 95% confidence interval, 0.6-2.0), but an increased risk was observed with smoking a cigarette soon (≤30 minutes) after waking (odds ratio, 2.1; 95% confidence interval, 1.0-3.8). The ratio of NNAL-Gluc to NNAL, a possible indicator of lung cancer risk, was significantly lower in menthol versus nonmenthol smokers. The NNAL-Gluc/NNAL ratio was 34% lower in Whites (P < 0.01) and 22% lower in Blacks. In subsequent human liver microsome studies, menthol inhibited the rate of NNAL-O-glucuronidation and NNAL-N-glucuronidation. Collectively, these results show that menthol does not affect biological exposure to tobacco smoke constituents but indicates that menthol might inhibit the detoxification of the potent lung carcinogen NNAL.

AB - Menthol is a controversial cigarette additive because its physiologic or pharmacologic effects may possibly increase the risk for cancer and its targeted market is the Black community. In a community-based cross-sectional study on 525 Black and White volunteers, we compared levels of urinary and plasma cotinine, plasma thiocyanate, urinary 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1- butanol (NNAL), and its detoxified form (NNAL-Gluc) between menthol and nonmenthol smokers. In regression models that adjusted for daily cigarette intake, no significant differences were observed in the concentration of these biomarkers by menthol status in both races. There was no significant association between high Fagerstrom nicotine dependence scores and the use of menthol cigarettes (odds ratio, 1.1; 95% confidence interval, 0.6-2.0), but an increased risk was observed with smoking a cigarette soon (≤30 minutes) after waking (odds ratio, 2.1; 95% confidence interval, 1.0-3.8). The ratio of NNAL-Gluc to NNAL, a possible indicator of lung cancer risk, was significantly lower in menthol versus nonmenthol smokers. The NNAL-Gluc/NNAL ratio was 34% lower in Whites (P < 0.01) and 22% lower in Blacks. In subsequent human liver microsome studies, menthol inhibited the rate of NNAL-O-glucuronidation and NNAL-N-glucuronidation. Collectively, these results show that menthol does not affect biological exposure to tobacco smoke constituents but indicates that menthol might inhibit the detoxification of the potent lung carcinogen NNAL.

UR - http://www.scopus.com/inward/record.url?scp=58349090455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58349090455&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0744

DO - 10.1158/1055-9965.EPI-08-0744

M3 - Article

C2 - 19124478

AN - SCOPUS:58349090455

VL - 18

SP - 35

EP - 41

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -